Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listORITAVANCIN

ORITAVANCIN

ORITAVANCIN Structural

What is ORITAVANCIN?

Absorption

Pharmacokinetic analysis of oritavancin revealed a Cmax of 138 and μg/mL and an AUC0-∞ of 2800 μg?h/mL. The AUC0-t in a study of healthy volunteers after an 800 mg dose 1,1111 μg?h/mL. was also be Another pharmacokinetic study reported a Cmax of 4.7-7.6 micrograms/mL, generally achieved within 24 hours of administration.

Toxicity

The LD50 of oritavancin in rats is >500m mg/kg. Prescribing information indicates no experience with overdose during the clinical program for oritavancin, however, an overdose is likely to result in an increased risk of adverse effects, such as headache, nausea vomiting, and diarrhea. This drug is not dialyzable, and in the case of an overdose, supportive measures should be undertaken.

Indications

Oritavancin is indicated for the treatment of adult patients with acute bacterial skin and skin structure (including subcutaneous) infection. It is used for confirmed/suspected infections with designated and susceptible gram-positive organisms. There are two preparations of oritavancin; the 400 mg dose that is administered over 3 hours, and the 1200 mg dose administered over 1 hour. Both are indicated for susceptible gram-positive skin and skin structure infections in adults.
As antimicrobial susceptibility patterns are geographically distinct, local antibiograms should be consulted to ensure adequate coverage of relevant pathogens prior to use.

Background

Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts the option of single-dose administration and has been proven as non-inferior to a full course of vancomycin therapy.
On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion. Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion and contains a lower dose of 400 mg. Marketed by Melinta Therapeutics, Kimyrsa offers effective and time-efficient treatment for skin and skin structure infections.

Definition

ChEBI: A semisynthetic glycopeptide used (as its bisphosphate salt) for the treatment of acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms including MRSA.

Pharmacokinetics

Oritavancin interferes with bacterial cell wall synthesis and integrity, treating susceptible skin and subcutaneous tissue infections with gram-positive bacteria. This drug is known to artifically increase INR and aPTT, interfering with coagulation testing. Cases of infusion reactions have also been reported.

Clinical Use

Antibacterial agent

Enzyme inhibitor

This novel, semi-synthetic glycopeptide antibiotic (FW = 1793.10 g/mol; CAS 171099-57-3), also known as LY333328, Orbactiv?, and (4R)-22-O- (3-amino-2,3,6-trideoxy-3-C-methyl-a-L-arabinohexopyranosyl)-N3-(p-(pchlorophenyl) benzyl)vancomycin, disrupts the cell membrane of Grampositive bacteria and inhibits both transglycosylation and transpeptidation. Oritavancin differs from vancomycin by the presence of a hydrophobic N-4-(4-chlorophenyl)benzyl substituent on the disaccharide, the addition of a 4-epi-vancosamine monosaccharide to the amino acid residue in Ring-6, and replacement of the vancosamine moiety by 4-epi-vancosamine. When compared vancomycin, teicoplanin, and quinupristin-dalfopristin (Synercid) against 219 strains of enterococci and staphylococci, including vancomycin-resistant enterococci and methicillinresistant methicillinresistant Staphylococcus aureus, LY333328 demonstrated superior activity against vancomycin-resistant enterococci and was the only antibiotic which was bactericidal. Indeed, a single infusion of this antibiotic (1200 mg) can clear serious bacterial skin infections, including methicillin-resistant Staphylococcus aureus, or MRSA, as effectively as the usual 7-10 day, twice-daily regimen of vancomycin now needed to treat patients.

Drug interactions

Potentially hazardous interactions with other drugs
Anticoagulants: possibly increases warfarin concentration.

Metabolism

In vitro studies on human hepatocytes suggest that oritavancin is not metabolized, and is excreted unchanged.

Metabolism

In vitro human liver microsome studies indicated that oritavancin is not metabolised. It is excreted unchanged; less than 1% and 5% of a dose is recovered in the urine and the faeces.

Properties of ORITAVANCIN

Density  1.59±0.1 g/cm3(Predicted)
storage temp.  Store at -20°C
solubility  Soluble in DMSO
pka 2.93±0.70(Predicted)

Safety information for ORITAVANCIN

Computed Descriptors for ORITAVANCIN

Related products of tetrahydrofuran

You may like

  • 1-Methyl-6-oxo-1,6-dihydropyridazine-3-carbonitrile 98%
    1-Methyl-6-oxo-1,6-dihydropyridazine-3-carbonitrile 98%
    99903-60-3
    View Details
  • 88491-46-7 98%
    88491-46-7 98%
    88491-46-7
    View Details
  • 1823368-42-8 98%
    1823368-42-8 98%
    1823368-42-8
    View Details
  • 2-(3-(tert-butyl)phenoxy)-2-methylpropanoic acid 1307449-08-6 98%
    2-(3-(tert-butyl)phenoxy)-2-methylpropanoic acid 1307449-08-6 98%
    1307449-08-6
    View Details
  • Ethyl 3-(furan-2-yl)-3-hydroxypropanoate 25408-95-1 98%
    Ethyl 3-(furan-2-yl)-3-hydroxypropanoate 25408-95-1 98%
    25408-95-1
    View Details
  • 2-Chloro-5-fluoro-1-methoxy-3-methylbenzene 98%
    2-Chloro-5-fluoro-1-methoxy-3-methylbenzene 98%
    1805639-70-6
    View Details
  • 1784294-80-9 98%
    1784294-80-9 98%
    1784294-80-9
    View Details
  • Lithium Clavulanate
    Lithium Clavulanate
    61177-44-4
    View Details
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.